This “Year in review” presents a selection of research themes and individual studies from the
clinical osteoarthritis (OA) field (epidemiology and therapy) and includes noteworthy …

The antimalarial hydroxychloroquine (HCQ) has demonstrated several crucial properties for
the treatment of systemic lupus erythematosus (SLE). Herein, we reviewed the main HCQ …

Objective To develop evidence-based European Alliance of Associations for Rheumatology
(EULAR) points to consider (PtCs) for the management of difficult-to-treat rheumatoid …

Nonsteroidal anti‐inflammatory drugs (NSAIDs) inhibit the enzyme cyclooxygenase (COX),
which forms prostaglandins involved in pain and inflammation. COX inhibitors have …

Osteoarthritis (OA) is a degenerative disease of middle-aged and elderly people, contributed
a higher burden of disease in China and the world. In 2017, under the support of the …

Knee osteoarthritis (KOA) is a common chronic articular disease worldwide. It is also the
most common form of OA and is characterized by high morbidity and disability rates. With the …

Osteoarthritis (OA) most commonly affects knee joints, and the next most commonly affected
sites are the hands and hips. Three distinct hand OA phenotypes have been described …

Objective To review the current state of pharmaceutical treatment recommendations for the
management of osteoarthritis. Method A narrative review was drafted to describe treatment …

Osteoarthritis (OA) is a highly prevalent condition, and the hand is the most commonly
affected site. Patients with hand OA frequently report symptoms of pain, functional limitations …

Objective To evaluate the quality of clinical practice guidelines (CPGs) for interventions in
management of osteoarthritis (OA) and to provide a synthesis of high‐quality CPG …